Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | FLT3 | P36888 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 1/20 | 1.00 |
| ▸ | RELA | Q04206 | 1/20 | 1.00 |
| ▸ | GFER | P55789 | 2/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.83 |
| ▸ | GABRP | O00591 | 1/20 | 0.83 |
| ▸ | GABRD | O14764 | 1/20 | 0.83 |
| ▸ | PIM1 | P11309 | 1/20 | 0.83 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.83 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.83 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pectolinarigenin SCHEMBL29606971 | 1.00 | MAPT (1.00) | MAPTFLT3MEN1KMT2ANPC1 | |
| SCHEMBL8063178 | 0.91 | FLT3 (0.83) | MAPTFLT3MEN1KMT2ANPC1 | |
| Hispidulin SCHEMBL29458970 | 0.91 | POLB (1.00) | MAPTFLT3MEN1KMT2ANPC1 | |
| Hispidulin SCHEMBL514926 | 0.91 | POLB (1.00) | MAPTFLT3MEN1KMT2ANPC1 | |
| SCHEMBL28732976 | 0.90 | FLT3 (0.81) | MAPTFLT3MEN1KMT2ANPC1 | |
| SCHEMBL29504103 | 0.90 | FLT3 (0.81) | MAPTFLT3MEN1KMT2ANPC1 | |
| SCHEMBL6242511 | 0.90 | KMT2A (0.81) | MAPTFLT3MEN1KMT2ANPC1 | |
| SCHEMBL737628 | 0.89 | FLT3 (0.81) | MAPTFLT3MEN1KMT2ANPC1 | |
| SCHEMBL17258304 | 0.89 | FLT3 (0.81) | MAPTFLT3MEN1KMT2ANPC1 | |
| Salvigenin SCHEMBL1427018 | 0.89 | FLT3 (1.00) | MAPTFLT3MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 441 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709365-A2 | FORMULATIONS OF PECTOLINARIGENIN | Debut Biotechnology, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4698662-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2024220449-A9 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2025-04-03 | — | — | WO | claimed |
| US-20250011393-A1 | FLAVONOID-COLLAGEN CROSSLINKED ANTIOXIDANT HYDROGEL | NORTH CAROLINA STATE UNIVERSITY | 2025-01-09 | — | — | US | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| WO-2024233739-A2 | FORMULATIONS OF PECTOLINARIGENIN | Debut Biotechnology, Inc. (US) | 2024-11-14 | — | — | WO | claimed |
| WO-2024220449-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2024-10-24 | — | — | WO | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-18 | — | — | US | claimed |
| WO-2003051287-A2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING RADIATION | THE QUIGLEY CORPORATION (US) | 2003-06-26 | — | — | WO | claimed |
| US-20030118536-A1 | Topical compositions and methods for treatment of adverse effects of ionizing radiation | QUIGLEY CORPORATION, THE | 2003-06-26 | — | — | US | claimed |
| US-20030105031-A1 | Methods for the treatment of skin disorders | QUIGLEY CORPORATION, THE | 2003-06-05 | — | — | US | claimed |
| US-20030103954-A1 | Oral compositions and methods for prevention, reduction and treatment of radiation injury | QUIGLEY CORPORATION, THE | 2003-06-05 | — | — | US | claimed |
| US-20030105027-A1 | Nutritional supplements and methods for prevention, reduction and treatment of radiation injury | QUIGLEY CORPORATION, THE | 2003-06-05 | — | — | US | claimed |
| WO-2003039452-A2 | NUTRITIONAL SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF RADIATION INJURY | THE QUIGLEY CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |
| US-6555573-B2 | Comprising a cold compounded mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor, antioxidant and carrier; side effect reduction; partial recovery of neurological function in some cases | THE QUIGLEY CORPORATION | 2003-04-29 | — | — | US | claimed |
| US-20020165207-A1 | Compositions and methods for the treatment of diabetic neuropathy | QUIGLEY CORPORATION, THE | 2002-11-07 | — | — | US | claimed |
| US-20020115618-A1 | Method and composition for the topical treatment of diabetic neuropathy | QUIGLEY CORPORATION, THE | 2002-08-22 | — | — | US | claimed |
| WO-2002049575-A2 | METHOD AND COMPOSITION FOR THE TREATMENT OF DIABETIC NEUROPATHY | THE QUIGLEY CORPORATION (US) | 2002-06-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030103954-A1 | Oral compositions and methods for prevention, reduction and treatment of radiation injury | FOXO3, BAX, GSTK1 | MAPT 4249/4885FLT3 4402/4885MEN1 3382/4885 |
| US-20030105027-A1 | Nutritional supplements and methods for prevention, reduction and treatment of radiation injury | FOXO3, NQO1, FOXO1 | MAPT 3987/4885FLT3 3778/4885MEN1 3289/4885 |
| US-20030105031-A1 | Methods for the treatment of skin disorders | TYR, CUTA, NFATC1 | MAPT 1999/4885FLT3 3965/4885MEN1 4748/4885 |
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | THPO, SERPINB1, SERPINC1 | MAPT 2717/4885FLT3 563/4885MEN1 740/4885 |
| US-20030118536-A1 | Topical compositions and methods for treatment of adverse effects of ionizing radiation | GSTK1, FOXO3, SIK2 | MAPT 3237/4885FLT3 3657/4885MEN1 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.